Return to In-Person Face-to-Face (FTF) Formal Meetings with FDA
Commencing 22 January 2024, the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) will expand in-person FTF industry meetings to include all meeting types. Sponsors should specify the request for a FTF meeting in their application. If agreed, FDA’s focus is on hybrid meetings, with only core participants with a primary speaking role participating in-person while others join virtually.
Final Guidance Documents Published
Rare Diseases: Considerations for the Development of Drugs and Biological Products
The selected issues discussed here are commonly encountered in rare disease drug development, for which there is often limited medical and scientific knowledge, poorly understood natural history data, sample size constraints, and lack of drug development experience. This guidance finalizes the draft guidance entitled “Rare Diseases: Common Issues in Drug Development” issued on 01 February 2019.
Data Standards for Drug and Biological Product Submissions Containing Real-World Data (RWD)
This guidance addresses considerations for the use of data standards currently supported by FDA in applicable drug submissions containing study data derived from RWD sources.
Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products
This guidance is aimed at Sponsors proposing to design a new registry or use an existing registry to support regulatory decision-making about a drug’s effectiveness or safety. It does not provide recommendations on choice of study design or statistical methods used to analyse data from registries.
Digital Health Technologies (DHT) for Remote Data Acquisition in Clinical Investigations
This guidance provides recommendations for ensuring that a DHT (hardware and/or wearable and software application) is fit-for-purpose and supports the interpretability of its data in a clinical investigation. It considers of both the DHT’s form (i.e., design) and function(s) (i.e., distinct purpose within an investigation).
Draft Guidance Documents out for Comment
Potency Assurance for Cellular and Gene Therapy (CGT) Products
This guidance includes recommendations for helping to assure the potency of CGT products at all stages of the product lifecycle and using an approach that is grounded in quality risk management. Submit Comments by 27 March 2024.
Master Protocols for Drug and Biological Product Development
This draft guidance addresses the design and analysis of trials conducted under a master protocol, as well as the submission of documentation to support their regulatory review. The primary focus is on randomized umbrella and platform trials intended to demonstrate safety and substantial evidence of effectiveness. Submit Comments by 22 February 2024.
Use of Real-World Evidence (RWE) to Support Regulatory Decision-Making for Medical Devices
FDA issued this draft guidance to clarify how to evaluate real-world data and provides expanded recommendations to Sponsors considering using RWE to support a regulatory submission for medical devices. Submit Comments by 20 February 2024.
Advanced Manufacturing Technologies (AMT) Designation Program
This draft guidance provides recommendations for those interested in participating in the AMT Designation Program. It outlines the eligibility criteria for AMT designation, the submission and assessment process for requests, and the benefits of receiving an AMT designation, plus a question-and-answer (Q&A) section covering key concepts important for program utilization. Submit Comments by 12 February 2024.
Quality Considerations for Topical Ophthalmic Drug Products
This guidance revises the draft guidance of the same name issued in October 2023. This revision adds microbiological considerations related to product sterility for all ophthalmic drug products and the prevention of contamination of products packaged in multidose containers. Submit Comments by 26 February 2024.
Breakthrough Therapies and PRIME Programs
The EMA–FDA joint Q&As on Quality and GMP aspects of PRIME/Breakthrough therapy applications document, published last month, provides general information and insight on the ongoing discussions between FDA and the EMA on this topic. The document is divided into four annexes, discussing: control strategy considerations, process validation approaches, alternatives for determination of re-test period or shelf-life, plus good manufacturing practice (GMP) considerations for PRIME/BT applications.